

Treatment Landscape of Relapsed/Refractory CLL in Low-Resource Countries

Muhammad Usman¹, Muhammad Khurram Islam², Safia Khan¹ and Muhammad Shahzad Sarwar¹, Abdul Wahid Ayub³
1 Pakistan Kidney and Liver Institute and Research Center (PKLI), Lahore, Pakistan
2 Sargodha Medical College / Dr. Faisal Masood Teaching Hospital, Sargodha, Pakistan
3 Allied Hospital, Faisalabad, Pakistan



INTRODUCTION

- Management of relapsed/ refractory chronic lymphocytic leukemia (R/R CLL) remains challenging in low-income countries because of delayed diagnosis, limited access to molecular testing, and restricted availability of novel targeted therapies.
- We reviewed real-world treatment patterns and outcomes of patients with R/R CLL managed in a resource-constrained setting.

AIM







- To evaluate real-world treatment patterns, therapeutic outcomes, and survival of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) managed in a resource-constrained setting.

METHOD

- A retrospective observational study was conducted on 20 patients with R/R CLL treated at a tertiary care center.
- Medical records were reviewed for demographic characteristics, indications for treatment, cytogenetic findings, first-line and second-line therapies, treatment duration, response, and treatment-related toxicities.

CONCLUSIONS

- Despite financial and diagnostic limitations in low-income countries, patients with R/R CLL can achieve favorable outcomes with targeted therapies such as BTK inhibitors and Venetoclax-based regimens.
- Improving affordability, access to molecular diagnostics and novel agents is essential to optimize care in resource-limited settings.



CONTACT INFORMATION

MBSS, FCPS (Clinical Haematology)
PKLI&RC, Lahore– Pakistan
Email. dr.usman.4496@gmail.com
Contact: +92 322 6005144

REFERENCES

R, Pavlovsky MA, Akinola NO, Varghese AM, Arrais-Rodrigues C. Management of Chronic Lymphocytic Leukemia in Less-Resourced Countries. *Cancer J.* 2021;27(4):314-319

Ud Din MA, et al. Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review. *Medicina (Kaunas).* 2023;59(8):1483. doi:10.3390/medicina59081483.